Online inquiry

IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3822MR)

This product GTTS-WQ3822MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets NCAM1 gene. The antibody can be applied in Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000615.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684
UniProt ID P13591
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3822MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15353MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ10163MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ4961MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ5443MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ9572MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ15759MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ13894MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ13680MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RC18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW